On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also ...
Ligand said it was terminating the program as a result of its claim that Viking "materially breached its obligation to use Commercially Reasonable Efforts to develop and commercialize the TR-Beta ...
Ligand Pharmaceuticals has accused Viking Therapeutics of breaching obligations under their licensing deal for thyroid hormone receptor beta (TRβ) therapies and moved to terminate the program. Viking ...
Q1 2026. Management View. Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabl ...
Just call it history revisited. Viking is setting sail again in China. The Viking Yi Dun completed her first voyage from Shanghai to Hong Kong (Shenzhen). Viking’s new itineraries include a domestic ...
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results